Glenmark Pharma will own 7.84% in GLS after the divestment. The transaction is subject to customary conditions precedent, including receipt of regulatory and shareholder approvals.
Pursuant to the transaction, Nirma will make a mandatory open offer to all public shareholders of GLS.
